雷公藤甲素防治脉络膜新生血管形成的研究进展  

Study on the prevention of choroidal neovascularization by Triptolide

作　　者：苏映雪[1] 姚向超[1] 吕迅羽[1] 曹琛[1] 梁光江[1] 王延东[1] 

机构地区：[1]中山大学中山眼科中心,广州510060

出　　处：《临床药物治疗杂志》2016年第6期6-10,共5页Clinical Medication Journal

基　　金：2015年广东省中医药局科研项目(20151168)

摘　　要：目的:介绍脉络膜新生血管(CNV)的病理机制及一线抗VEGF药物的特点,探讨雷公藤甲素(TP)防治CNV形成的可行性。方法:通过对国内外相关文献资料的整理、对比和分析,总结TP在新生血管形成过程中的作用及分子机制,分析TP抑制CNV形成的可行性。结果与结论:我们认为TP具有防治CNV形成的功效,作用机制可能与其抑制HIF-1通路、VEGF通路及Dll4-Notch通路有关。笔者为评估TP是否可作为防治CNV形成的新药提供实验依据。Objective： To review the pathomechanism of choroidal neovascularization（CNV） and the characteristics of first-line anti-VEGF drugs, and investigate the feasibility of triptolide（TP） in preventing CNV. Methods： Relevant research literatures published recently were compared, analyzed and evaluated. The function and molecular mechanisms of TP in neovascularization was summarized, and the feasibility of TP in inhibiting CNV formation was analyzed. Results and Conclusion： We further find that TP＇s anti-CNV activity mainly results from that it can inhibit HIF-1, VEGF and Dll4-Notch signaling pathway. This review assesses whether TP can be a candidate molecular used as a new drug in preventing CNV and provides experimental basis.

关 键 词：雷公藤甲素 脉络膜新生血管 分子机制 

分 类 号：R774.1[医药卫生—眼科] R285.5[医药卫生—临床医学]